Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 6/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.51 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13432159 | 0.89 | POLB (0.45) | PDE1APDE1BPDE1CPOLB | |
| SCHEMBL19703352 | 0.88 | PDE1A (0.51) | PDE1APDE1BPDE1CPDE4DMAPK1 | |
| SCHEMBL24282841 | 0.85 | POLB (0.48) | POLB | |
| SCHEMBL29769207 | 0.85 | POLB (0.43) | PDE1APDE1BPDE1CPOLB | |
| SCHEMBL15339575 | 0.85 | POLB (0.43) | PDE1APDE1BPDE1CPOLB | |
| SCHEMBL15325873 | 0.84 | KDM1A (0.52) | POLB | |
| SCHEMBL30122245 | 0.82 | PIK3CD (0.47) | PDE1APDE1BPDE1CPDE4DMAPK1 | |
| SCHEMBL15910642 | 0.82 | PIK3CD (0.47) | PDE1APDE1BPDE1CPDE4DMAPK1 | |
| Hydrochloric Acid SCHEMBL15655447 | 0.82 | KDM1A (0.51) | POLB | |
| SCHEMBL15341864 | 0.82 | MAPK1 (0.50) | PDE1APDE1BPDE1CPDE4DMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PDE1A 4751/4885PDE1B 4588/4885PDE1C 4803/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PDE1A 4751/4885PDE1B 4588/4885PDE1C 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.